INTRODUCTION
A large superfamily (> 50 members) of monomeric GTPbinding proteins structurally related to the ras oncogene proteins has been described in the past few years (Bourne et al., 1991; Grand and Owen, 1991; Hall, 1990; Valencia et al., 1991) . These proteins have been implicated in the regulation of a diverse array of cellular processes, utilizing their ability to bind and hydrolyse GTP as a means to regulate the reversible interactions and/or activities of macromolecules involved in these processes. Based upon sequence homology, the ras superfamily can be divided into four subfamilies, ras, rho, rab and arf (Valencia et al., 1991; Kahn et al., 1992) . The ras proteins are essential components of receptor-mediated signaling pathways controling cell proliferation and differentiation; the rho proteins are involved in cytoskeletal assembly and NADPH oxidase regulation in phagocytes; and the rab and arf proteins regulate the transport of vesicles between intracellular compartments and/or the plasma membrane (see Hall, 1990) .
The mammalian rap proteins, which are the focus of this Review, are members of the ras family of GTP-binding proteins,and share highly conserved structural motifs with the ras transforming proteins. Overall, the rap proteins share -50% sequence similarity with ras and, like ras, are found in nearly all tissues. Two rap families, designated rapl and rap2, have been identified to date. Within each family are two members denoted as A and B, i.e. raplA and raplB (see Figure 1) . As is the case with the majority of the low-molecular-mass GTP-binding proteins, the actual role(s) of the Rap proteins in cellular function have not yet been elucidated in detail. There is evidence however that Rap proteins exert biological activities in at least two cellular arenas: first in that of cellular growth and differentiation control, and secondly in a phagocyte-specific enzyme system responsible for the generation of microbicidal oxygen radicals. The latter suggests either that Rap can play very specific biological roles in certain cells or, alternatively, that Rap serves a very general function which can involve different proteins and different effector systems depending on the cell involved. In this Review, I examine current knowledge of the biology of the Rap proteins.
CLONING AND ISOLATION OF RAP PROTEINS
The Rap proteins were cloned and/or purified by a number of laboratories within a very short time period by using a variety of strategies. Pizon et al. (1988a) identified the raplA and rap2A genes by screening a Raji human Burkitt lymphoma cell library with probes based upon the Dras3 gene previously identified in Drosophila (Schejter and Shilo, 1985) . This Drosophila rasrelated protein differed from the other members of the ras superfamily known at that time in that it possessed a threoninefor-glutamine substitution at residue 61 of the highly conserved DTAGQE sequence found in positions 57-62 of ras. raplB was identified very soon afterward by Pizon et al. (1988b) using the same strategy. raplA (termed Krev-1) was isolated by Kitayama et al. (1989) from a human fibroblast cDNA expression library based on its ability to cause reversion of the transformed phenotype of v-Ki-ras-transformed DT fibroblasts. Kawata et al. (1988) purified a 22 kDa GTP-binding protein (termed smg p21) from bovine brain, sequenced, and cloned the protein, and found it to be identical to raplB. Takai's laboratory has subsequently purified RaplB from human platelets (Ohmori et al., 1989) and bovine aortic smooth muscle (Kawata et al., 1989a) . RaplA has also been purified, sequenced, and cloned from human neutrophils (Bokoch et al., 1988; Quilliam et al., 1990) . The identification of a fourth member of the rap family, rap2B, emerged through molecular cloning from a platelet cDNA library (Ohmstede et al., 1990) . rapl and rap2 proteins are 700% identical at the amino acid level (Figure 1 ). raplA and lB differ by only nine out of 184 amino acids (95 % identity), with the sole region of substantial nonidentity being between positions 171-189 of the C-terminus. Similarly, rap2A and 2B differ by 18 out of 183 amino acids (90% identity), with the major area of divergence at residues 170-183 of the C-terminus.
POST-TRANSLATIONAL MODIFICATION OF RAP PROTEINS Isoprenylatlon
It has been established that a diverse group of yeast and mammalian proteins are modified post-translationally by the covalent addition of an isoprenoid group (reviewed by Maltese, 1990; Cox and Der, 1992) . This event is usually signalled by a Cterminal CAAX motif (C, cysteine; A, aliphatic; X, any residue) present in the proteins. The sequence of events involved in posttranslational processing of the low-molecular-mass GTP-binding proteins includes the addition of a C15 (farnesyl) or a C20 (geranylgeranyl) isoprenyl group to the cysteine residue of the CAAX motif via a thioether linkage, proteolytic cleavage of the AAX residues, and carboxylmethylation of the now terminal and isoprenylated cysteine. While the specific contribution of isoprenoid modification to protein function is not known, it is apparent that such modifications are critical for the biological activities of isoprenylated proteins.
Like many of the other members of the ras superfamily, the Rap proteins contain a C-terminal CAAX consensus motif which directs post-translational isoprenylation (Maltese, 1990) . RaplA, ending in CLLL, has been shown to be modified by a geranylgeranyl group at Cys-181, with proteolytic truncation and subsequent carboxylmethylation also shown to take place (Buss et al., 1991) . RaplB and Rap2B, ending in CLQL and CVIL, appear to undergo similar modifications (Kawata et al., 1990; Winegar et al., 1991) . Carboxylmethylation of RaplB (Huzoor-Akbar et al., 1991) and RaplA (Quilliam and Bokoch, 1992) has been found to be stimulated by guanosine 5'-[ythio]triphosphate (GTPyS); the significance of this interesting observation in terms of Rap modification and function in vivo is unknown, but suggests the possibility of regulatory significance for this modification.
It appears to be a general rule that isoprenylated proteins terminating in leucine are geranylgeranylated, while those ending in serine or methionine are farnesylated (Moores et al., 1991; Cox and Der, 1992) . It is of note that Rap2B, which terminates in CVIL, is geranylgeranylated while the very closely related Rap2A, which terminates in CNIQ, is farnesylated (Farrell et al., 1992) . These two structurally similar forms of Rap may thus partition into different membranes within cells, perhaps reflecting distinct biochemical activities. The concept that farnesylation versus geranylgeranylation of a low-molecular-mass GTP-binding protein may impart specific functions and/or subcellular localizations to that protein has been explored to a limited extent. A chimaeric protein containing the N-terminal half of oncogenic H-Ras linked to the C-terminal half of RaplA was geranylgeranylated and retained the ability to transform cells (Buss et al., 1991) . Cox et al. (1992) found that switching the Cterminal CAAX sequences of H-Ras and RaplA did not prevent oncogenic Ras activity, nor the ability of RaplA to antagonize Ras transforming activity. Farnesyl and geranylgeranyl moieties are thus functionally interchangeable for these biological activities. However, in this same study the expression of moderate levels of geranylgeranyl-modified normal Ras inhibited the growth of untransformed NIH 3T3 cells. These findings suggest that normal Ras function may specifically require protein modification by a farnesyl isoprenoid. Whether this reflects any changes in the subcellular localization of the chimaeric proteins however was not examined in this study.
The reported subcellular distribution of the Rap proteins seems to be distinct from that of Ras (see Grand and Owen, 1991) . Both Beranger et al. (1991a) and Kim et al. (1990) observed RapI to be associated with subcellular fractions devoid of Ras. Beranger et al. (199la) showed by immunofluoresence labelling and co-fractionation with Golgi-specific markers that Rapl was associated with a Golgi-like structure in Rat-I fibroblasts and HEP2 epidermoid carcinoma cells, while Ras was clearly detected in plasma membrane. Similarly, Rap2 was observed to associate with a low density structure that morphologically overlapped with the endoplasmic reticulum in Rat-I cells (Beranger et al., 1991b) . The structural and/or functional basis for this differential subcellular localization of Rap and Ras has not yet been determined. RapI and Rap2 proteins have been localized to both the plasma membrane and specific granules of Quinn et al., 1992a) . This may relate to the role of RapI in the NADPH -oxidase system of phagocytic cells (discussed below).
Phosphorylation
After the purification of RaplA and Rap IB, these proteins were soon found to serve as substrates for phosphorylation by cyclic AMP-dependent protein kinase in vitro Hoshijima et al., 1988; Kawata et al., 1989b; Lerosey et al., 1991; Quilliam et al., 1991) . Both Rap proteins incorporate phosphate to a level of 1 mol/mol, suggesting a single site of phosphorylation. The site at which phosphorylation occurs has been shown to be Ser-180 in RaplA . This is contained within the sequence KKKPKKKSC, which is similar to consensus cyclic AMP-dependent protein kinase phosphorylation sites (Kemp and Pearson, 1990) . RapIB is phosphorylated solely on Ser-1 79 within the sequence GKARKKSSC, again similar but not identical to "classical " cyclic AMP-dependent kinase motifs . In contrast, the Rap2 proteins lack such (potential) consensus motifs for phosphorylation near the C-terminus and do not serve as substrates for phosphorylation by cyclic AMP-dependent, or any known, protein kinases.
Phosphorylation is not influenced by whether Rap is in a GDP-bound versus GTP-bound state, and stoichiometric phosphorylation of RaplA or lB in vitro has no effect on the guanine nucleotide-binding or hydrolysis properties of the two proteins, nor the responsiveness to Rap-GAP Hoshijima et al., 1988) . The phosphorylation sites of both RaplA and RaplB are adjacent to the cysteine residue which is geranylgeranylated. Possible influences of the phosphorylation on post-translational processing of either Rap protein remain to be investigated. A role for RapI phosphorylation in regulating the interaction of RapI with other macromolecules will be discussed below.
Phosphorylation of RaplA has been shown to occur in intact HL-60 cells which had been differentiated into neutrophil-like cells in response to dibutyryl cyclic AMP, forskolin, prostaglandin E1 or isoprenaline . Phosphorylation of RaplB occurs in human platelets in response to prostaglandin E1 or the prostacyclin analogue iloprost (Kawata et al., 1989b; Lapetina et al., 1989; Siess et al., 1990) . A form of Rapl has also been found to be phosphorylated in intact fibroblasts by exposure to 8-bromo cyclic AMP . The possibility that Rap may mediate some of the cellular effects of cyclic AMP will be considered later in this Review.
The Rap proteins clearly do not serve as substrates for protein kinase C, myosin light chain kinase or insulin/EGF receptor tyrosine kinases in vitro Hoshijima et al., 1988; Kawata et al., 1989b; Quilliam et al., 1991) . Recently however, RaplB has been reported to be phosphorylated by cyclic GMP-dependent protein kinase (Miura et al., 1992) and a neuronal calcium/calmodulin-dependent protein kinase (Sahyoun et al., 1991) Kawata et al., 1988; Lerosey et al., 1991) . The rate of GTP binding to Rap is limited at physiological concentrations of Mg2" by the dissociation of GDP frQm the protein, suggesting that such exchange must be catalysed in vivo by other protein(s). Hydrolysis of GTP to GDP also occurs at a very low rate on the Rap proteins (0.0005-0.010 mol/min), and would be too low to terminate the action of Rap-GTP effectively without some means to enhance GTP hydrolysis. GTPaseactivating proteins (GAPs) which stimulate the rate of GTP hydrolysis by Rap have been identified and are described below. A second regulatory protein, capable of stimulating the dissociation of GDP/GTP from Rap (Rap GDS), has also been purified and cloned (see below).
GTPase-activating proteins (GAPs) Several GAP activities that appear to be specific for Rapl have been detected in the plasma membrane and cytosol of a number of cell types. Polakis et al. (1991) purified a membrane-associated 88 kDa GAP from HL-60 cells. This GAP was subsequently cloned and shown to be a unique protein which did not exhibit similarity to any of the GAPs specific for Ras . This form of Rap-GAP was not ubiquitously expressed, and was most abundant in fetal tissues and certain tumour cell lines. Interestingly, the expression of the 88 kDa Rap-GAP was decreased in HL-60 cells which had been induced to differentiate by dimethyl sulphoxide.
Two chromatographically resolvable peaks of Rap-GAP activity have been observed in human platelets (Ueda et al., 1989) and bovine brain cytosol. One such cytosolic GAP was purified (Nice et (Polakis et al., 1992) suggest that Rap-GAP may be regulated in a very specific manner in order to control Rap activity.
GDP/GTP dissociation stimulator (GDS)
A guanine nucleotide exchange protein which is active on Rapl has been identified and purified from bovine brain cytosol (Yamamoto et al., 1990) . This 53 kDa protein has been cloned and shown to be a unique protein with limited amino acid sequence similarity to the CDC25 and SCD25 proteins which may regulate the GDP/GTP exchange reaction of the yeast Ras 2 protein. Rap-GDS appears to interact with Rap 1 A and lB as a 1: 1 stoichiometric complex (Kawamura et al., 199 la). This interaction involves, at least in part, the Cterminal portion of Rapt, as indicated by: (a) the requirement for the post-translationally processed form of RapI for GDS binding and activity ; (b) the demonstration that proteolytic removal of an -1000 Da fragment of the C-terminus prevents binding and activation of Rapl by GDS ; (c) geranylgeranylated synthetic peptides representing the C-terminus of Rap t inhibit GDS action (Shirataki et al., 1991); phosphorylation of RaplB at the C-terminus enhances its interaction with GDS Itoh et al., 1991) . It is of interest that this " Rap l-GDS" is also able to catalyse GDP/GTP exchange for other post-translationally processed low-molecular-mass GTP-binding proteins, including K-Ras, Rho A and Racl . These proteins have in common a lysine/arginine-rich cationic region at their C-terminus which may enable them all to interact with the GDS.
A number of anionic phospholipids have been reported to antagonize the GDP/GTP exchange activity of Rap-GDS, and to reduce markedly the ability of GDS to stimulate Rapt B GTP binding (Kawamura et al., 1991b) . The effect of these lipids was reduced when Rap lB was phosphorylated by cyclic AMPdependent protein kinase (Itoh et al., 1991) . Takai and associates (Itoh et al., 1991; Kawamura et al., 1991b) (Labadia et al., 1992) or phosphatases] able to inhibit Ras growth signals (see Figure 2 ).
In support of the "competition" hypothesis, Kitayama et al. (1990a) showed that an Asp-38 -->Ala or Asn point mutation in the effector domain of raplA markedly inhibited the ability of raplA to cause phenotypic reversion of ras-transformed cells. (Ala--> Thr), which are thought to activate rapt by maintaining it in the GTP-bound form (by analogy with ras), substantially enhanced its reversion-inducing activity. The latter observation suggested that raplA was more "active" in the GTP-bound form.
More direct evidence that such a competitive model of Rap action was possible came from studies by Hata et al. (1990) and Frech et al. (1990) . Both groups used purified components in vitro to demonstrate that RaplA (Frech et al., 1990) or lB (Hata et al., 1990 ) was able to compete with Ras for binding to Ras-GAP. Binding to Ras-GAP was more effective when Rapl was bound with GTP than with GDP, with Frech et al. (1990) reporting that the GDP form of RaplA had an affinity of at least 100-fold less than the GTP form, while Hata et al. (1990) only found a 2-3-fold difference between the two forms of RaplB.
Ras-GAP did not stimulate GTP hydrolysis by Rapl, as described in , suggesting that the association of RaplA with GAP produced a catalytically-inactive complex. an interaction which may be regulated by cyclic AMP, GTP is exchanged for GDP on Rapl, producing the "active" form of Rapl. This active Rapl may exert biological activities of its own, or may act in concert with GAPRP to pass on downstream signals. The Rapl -GTP form has a high affinity for Ras-GAP (GAPRS), effectively binding to GAPRS to form a presumably inactive complex.
This interaction would account for the anti-oncogenic action of Rapl toward Ras. (3) Rapl-GTP binds to GAPRp, which could represent an active signalling complex or (4) which catalyses the hydrolysis of Rapl-GTP to GDP, causing Rapl to dissociate from GAPRp and return to the " inactive" state. (5) Ras with GDP bound also represents an " inactive" state which (6) is acted on by a Ras-active GDS (GDSRS) to exchange bound GDP for GTP, producing a biologically "active" Ras. (7) Ras-GTP binds to GAPRS, leading to the generation of signals which result in the biological manifestations of Ras activity. (8) The action of GAPRS converts Ras to the GDP form, which releases GAPRs and returns to the initial "inactive" state.
Interestingly, the affinity of RaplA-GTP for Ras-GAP was 50-100-fold greater than that of Ras-GTP. Since the concentration of RapI in cells such as platelets (Ohmori et al., 1989) and neutrophils seems to be at least 10 times greater than that of Ras, this suggests that RaplA might be able to limit the amount of GAP available for interaction with Ras in vitro.
The ability of RaplA to antagonize Ras action by a competitive mechanism in an intact membrane system was demonstrated by Yatani et al. (1991) . This study utilized the M2 muscarinic receptor-regulated K+ channel of atrial membranes, which is inhibited by the action of Ras and Ras-GAP acting in concert (Yatani et al., 1990) . Using a patch-clamp technique to manipulate the levels of RaplA, Ras and GAP in the system, it was shown that: (1) RaplA antagonized the effect of Ras-GAP on channel opening in a manner that was inversely proportional to the level of GAP added; (2) antagonism was dependent on an intact effector domain in RaplA; (3) the inhibitory effect of RaplA could be overcome by the addition of exogenous Ras; and (4) RaplA did not antagonize a form of GAP (GAP32) whose ability to inhibit M2 muscarinic receptor-regulated K+ channels was independent of Ras. These results indicated that RaplA was acting by a competitive mechanism, and that such inhibition could occur at picomolar concentrations of RaplA, levels which are likely to occur in normal cells. The ability of RaplA to suppress Ras-GAP action in this system, and also the antagonistic activity of Rap lB in Xenopus oocytes (Campa et al., 1991) , indicates that this biological activity of RapI is not limited to the pathway leading to cell transformation by Ras. These studies also indicate that the antagonism of Ras action by Rapl occurs via a competitive mechanism involving the "effector domain" of Rapl. A number of studies have localized the suppressive activity of Rapl to the N-terminal portion of the molecule (Buss et al., 1991; Kitayama et al., 1990b; Zhang et al., 1990) , and have identified residues 26, 27, 30, 31 and 45 as crucial in this regard Nur-e-Kamal et al., 1992) . It is of interest then to note that both of the Rap2 proteins, as well as R-Ras, also contain an "effector domain" identical to Ras, yet do not suppress the ability of Ras to transform cells (Schweighoffer et al., 1990; Jimenez et al., 1991) . Although R-Ras differs from Rapl in the crucial amino acids adjacent to the "effector domain", Rap2 is identical to Rapl in these positions. Consideration of these facts indicates that additional structural components need to be accounted for in order to understand antagonism of Ras by Rap .
The physiological significance of the inhibition of Ras action by Rapl is still uncertain. There is as yet little data to indicate that Rap I plays such a regulatory role in normal cells. In fact, in some cell models of Ras action, Rapl has been reported not to inhibit the actions of Ras (Schweighoffer et al., 1990) . In yeast, mammalian rap genes can stimulate some of the same effector pathways as does H-ras (Xu et al., 1990; Ruggieri et al., 1992) . It should be pointed out that most models we have discussed here to explain Rap suppression of Ras activity are based on the idea that Ras-GAP serves a downstream signalling function that can be disrupted by Rap (see Figure 3) . If, in fact, Ras-GAP acts solely as a negative regulator of Ras activity in certain cells by keeping it in a GDP-bound state, then disruption of the binding of GAP to Ras could actually result in increased Ras activity! It is tempting to speculate that, if RapI is indeed a physiological suppressor of Ras function, modulation ofthe guanine nucleotide state of Rapl would play an important role in regulating the transduction of growth and differentiation signals via Ras (see Figure 3) . One could thus envisage that changes in the activity of Rapl GAPs and GDSs, etc., would also produce marked effects on Ras activity indirectly through their ability to regulate Rapl-GTP formation and thus binding to Ras-GAP(s). Mutations in Rapl or in Rapl-associated regulatory components might then play a significant role in the pathogenesis of mammalian tumours. A marked decrease in the levels of expression of rapl mRNA was reported in several types of tumours not normally associated with ras mutations (e.g. salivary gland fibrosarcomas and adenocarcinomas) by Culine et al. (1989) . raplB has been mapped to a chromosomal location near breakpoints associated with a number of malignant and benign neoplasms (Rousseau-Merck et al., 1990) . Several investigations of Rapl levels (Hong et al., 1990; Hsu and Gould, 1991) and loss of heterozygosity (Young et al., 1992) (Clark, 1990) . This respiratory burst is catalysed by the NADPH oxidase, a multicomponent enzyme composed of at least four known proteins (see Figure 4) .
A cytochrome b,,8, consisting of 91 kDa (gp91phox) and 22 kDa (gp22phox) subunits, resides in the plasma membrane and membrane of neutrophil-specific granules where it serves as the terminal electron carrier of the oxidase. Two additional cofactors, P47phox and p67phoX' are cytosolic and may exist as preformed complexes which translocate to the plasma membrane upon phagocyte activation, becoming integral parts of the active oxidase (Clark, 1990; Curnutte, 1992) .
Guanine nucleotides, specifically GTP, have been shown to be absolutely required for NADPH oxidase activity in cell-free assay systems (Peveri et al., 1992; Uhlinger et al., 1991) ,
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supporting the idea of a GTP-binding protein being involved in oxidase regulation (Bokoch, 1990) . Bokoch and Prossnitz (1992) have also shown that treatment of HL-60 cells with drugs able to block isoprenoid metabolism prevents a respiratory burst response in these cells after they have been differentiated into a neutrophil-like form by dimethyl sulphoxide. This isoprenoid requirement is presumably due to the need for isoprenoids in the post-translational processing of a low-molecular-mass GTPbinding protein. Indeed, Rac2 (Knaus et al., 1991) and possibly Racl (Abo et al., 1991) have been identified as important stimulatory regulators of the NADPH oxidase in human neutrophils. There are indications though that RaplA must also play some modulatory role in this system. The first suggestion of this came when Quinn et al. (1989) observed the co-isolation of a 22 kDa protein distinct from the cytochrome b 22 kDa subunit during purification of the cytochrome b oxidase component. This protein had an N-terminal amino acid sequence identical to that of Rapl. Evidence that this co-purification was not merely fortuitous (since Rapl could be separated from the cytochrome at a final sucrose gradient step) was provided by their observation that RapI present in neutrophil extracts would also bind to anticytochrome 91 kDa or 22 kDa antibody columns.
These observations were confirmed and extended by in vitro studies using a pure cytochrome preparation and purified baculovirus-Sf9 cell recombinant RaplA or RaplA purified from human neutrophils . Complexes between the two purified proteins were detected by gel filtration analysis. Formation of complex appeared to occur through the 1:1 association of RaplA with the cytochrome. These results demonstrated that RaplA binds directly to the cytochrome itself. The ability of RaplA to interact with the cytochrome when it was in a GDP versus GTPyS-bound state was also examined. RaplA bound to cytochrome in both the GTP and GDP forms; it appeared that the interaction was more stable when RaplA was complexed with GTPyS, however, since the ability to observe the RaplA-GDP-cytochrome complex was variable.
Agonists which elevate cyclic AMP in neutrophils are able to attenuate the respiratory burst in these cells (Rivkin et al., 1975; Sha'afi and Molski, 1988; Mueller et al., 1988) . Since RaplA can be phosphorylated by cyclic AMP-elevating agents in intact HL-60 cells , and stoichiometric phosphorylation of RaplA in vitro does not affect its ability to bind or hydrolyse guanine nucleotides, nor to respond to a cytosolic Rap-GAP Bokoch and Quilliam, 1990) , the possibility of effects on RaplA-cytochrome binding was examined. Bokoch et al. (1991) observed that the ability of phosphorylated Rap1A-GTPyS to form complexes with cytochrome b was markedly reduced. A potential mechanism by which elevations in neutrophil cyclic AMP could inhibit the respiratory burst response, therefore, is by modulation of Rap 1 A-cytochrome interactions.
It is of note that RaplB phosphorylation has been shown to enhance its ability to bind and be stimulated by a GDS Itoh et al., 1991) . It is possible that RapI phosphorylation serves a general regulatory role for this low-molecularmass GTP-binding protein. Thus, the interaction of RaplA and 1 B with other macromolecules at the C-terminus is postulated to occur, and to be modulated, either positively or negatively, by Rapl phosphorylation. Such regulation could also extend to KRas, which has a similar cationic region at its C-terminus and which has been reported to undergo C-terminal phosphorylation as well (Ballester et al., 1987) .
While it has been established that RaplA can interact with the NADPH oxidase-associated cytochrome b, the significance of function. Eklund et al. (1991) have reported that an antiserum against a synthetic peptide corresponding to the effector region of RaplA (amino acids 31-43) was able to totally inhibit oxidase activity in a cell-free system and that activity could be restored by addition of recombinant RaplA. Similar experiments have proven unsuccessful in our laboratory (G. M. Bokoch, unpublished work) . Recently, Mizuno et al. (1992) have also reported that RapI was inactive in supporting oxidase activity in a cell-free system. The reasons for these discrepancies are not yet clear. Several laboratories (Maridonneau-Parini and de Gunzburg, 1992; Quilliam et al., 1991; Quinn et al., 1992a) only find Rap in neutrophil membrane fractions when localized by specific immunblotting, in contrast to Eklund et al. (1991) , who report RapI to be cytosolic and to translate from cytosol to membrane upon neutrophil activation by phorbol myristate acetate. The functional role of RaplA in the NADPH oxidase system is thus not clear. It is possible that RaplA (unlike Rac2) may play a more subtle role in the system which may not be evident in studies using cell-free assays, which clearly rely on non-physiological activators in a structurally disrupted system. For example, based upon studies of the BUDI (or RSR1) RaplA homologue in Saccharomyces cerevesiae which indicate it is crucial for positional information relevant to bud site selection (Ruggieri et al., 1992) and upon data which indicate an association of RaplB with the platelet cytoskeleton upon thrombin activation (Fischer et al., 1990) , it is possible that RaplA in the neutrophil might direct translocation of cytochrome b to specific membrane sites upon cell activation or might mediate interactions between oxidase components and the cell cytoskeleton. Such interactions are thought to be important for oxidase activation and deactivation in vivo (Clark, 1990; Heyworth et al., 1991; Nauseef et al., 1991) and would be undetectable in normal cell-free oxidase assays. Recently, Quinn et al. (1992b) , where cyclic AMP inhibits activity of the NADPH oxidase, and in human platelets (Lazarowski et al., 1990) , where activation of phospholipase C is blocked by cyclic AMP. Finally, there are indications that Rap activity may be regulated by hormones in vivo through actions on its GAP (Marti and Lapetina, 1992) . The concept that the activity of Rap and other low-molecular-mass GTP-binding proteins may be regulated by the seven-transmembrane-spanning-domain receptors classically linked to the heterotrimeric G-proteins and/or that Rap might regulate the activity of these receptors in turn (Yatani et al., 1991) is an exciting one, with widespread implications for the integration of cell functions.
The association of RaplA with the NADPH oxidase cytochrome b component in human neutrophils is more difficult to assess. Unlike oxidase regulation by Rac2, a GTP-binding protein which is expressed solely in cells of haematopoietic lineage (Didsbury et al., 1989) Hall, 1992; Marx, 1992) . It is apparent from yeast genetic studies (Chant and Herskowitz, 1991) that the yeast homologue of RaplA (BUDI) may interact with CDC42 to co-ordinate bud site selection and assembly. CDC42 is a low-molecular-mass GTP-binding protein which is closely related to Rac (Shinjo et al., 1990; Didsbury et al., 1989 
